Quantification of von Willebrand factor and ADAMTS-13 after traumatic injury: a pilot study

Taleen A MacArthur,1 Julie Goswami,1 Laurie Moon Tasson,2 Alexander Tischer,2 Kent R Bailey,3 Grant M Spears,3 Jing-Fei Dong,4 Matthew Auton,5 Rosemary Kozar,6 Myung S Park7

ABSTRACT

Background Von Willebrand factor (VWF) is an acute phase reactant synthesized in the megakaryocytes and endothelial cells. VWF forms ultra-large multimers (ULVWF) which are cleaved by the metalloprotease ADAMTS-13, preventing spontaneous VWF–platelet interaction. After trauma, ULVWF is released into circulation as part of the acute phase reaction. We hypothesized that trauma patients would have increased levels of VWF and decreased levels of ADAMTS-13 and that these patients would have accelerated thrombin generation.

Methods We assessed plasma concentrations of VWF antigen and ADAMTS-13 antigen, the Rapid Enzyme Assays for Autoimmune Diseases (REAADS) activity of VWF, which measure exposure of the platelet-binding A1 domain, and thrombin generation kinetics in 50 samples from 30 trauma patients and an additional 21 samples from volunteers. Samples were analyzed at 0 to 2 hours and at 6 hours from the time of injury. Data are presented as median (IQR) and Kruskal-Wallis test was performed between trauma patients and volunteers at both time points.

Results REAADS activity was greater in trauma patients than volunteers both at 0 to 2 hours (190.0 (132.0–264.0) vs. 92.0 (71.0–114.0), p<0.002) and at 6 hours (167.5 (108.0–312.5.0) vs. 92.0 (71.0–114.0), p<0.001). ADAMTS-13 antigen levels were also decreased in trauma patients both at 0 to 2 hours (0.84 (0.51–0.94) vs. 1.00 (0.89–1.09), p=0.010) and at 6 hours (0.653 (0.531–0.821) vs. 1.00 (0.89–1.09), p<0.001). Trauma patients had accelerated thrombin generation kinetics, with greater peak height and shorter time to peak than healthy volunteers at both time points.

Discussion Trauma patients have increased exposure of the VWF A1 domain and decreased levels of ADAMTS-13 compared with healthy volunteers. This suggests that the VWF burst after trauma may exceed the proteolytic capacity of ADAMTS-13, allowing circulating ULVWF multimers to bind platelets, potentially contributing to trauma-induced coagulopathy.

Level of evidence Prospective case cohort study.

INTRODUCTION

The physiological response to trauma causes vascular damage directly through physical injury and indirectly through the acute phase response. Von Willebrand factor (VWF) is an important acute phase reactant synthesized in the megakaryocytes and endothelial cells (EC) as a single-chain propolypeptide of 2813 amino acids with repeat domains of D1-D2-D’-D3-A1-A2-A3-D4-C(1-6)-CK.12 Pro-VWF monomers form dimers through the CK domain, a variable number of dimers, then multimerize through the N-terminal disulfide bonds. This gives VWF a multidomain structure accessible to multiple cellular receptors.3-4 After synthesis, VWF multimers are either constitutively released into circulation or stored in the Weibel-Palade bodies of ECs and the alpha granules of platelets and megakaryocytes, where they form ultra-large VWF (ULVWF) multimers.9-11 In addition to their increased weight, these ULVWF multimers are intrinsically active and able to form high strength bonds with the GPIbα-binding subunit of the GP Ibα-IX-V complex on platelets and trigger platelet aggregation.9 12 12

On release from activated ECs, ULVWF multimers are anchored to the EC surface, elongated by the fluidic shear stress, and rapidly but partially cleaved by the metalloprotease ADAMTS-13 to generate VWF multimers found in circulation. Under physiological conditions, these cleaved circulating VWF multimers adopt globular structures that bury the GPIbα-binding A1 domain so that they cannot spontaneously bind platelets.13-19 During acute injury, however, ULVWF multimers are released from activated or injured ECs as part of the acute phase reaction.20-24 When their release overwhelms the proteolytic capacity of ADAMTS-13, ULVWF multimers cannot be quickly cleaved to the circulating form, resulting in the accumulation of ULVWF multimers in plasma and on platelet and EC surfaces, contributing to thrombosis (figure 1).9 12 12 25

The role of VWF in trauma and trauma-induced coagulopathy (TIC) is incompletely understood. TIC describes a state of dysregulated coagulation after trauma with both hypocoagulable and hypercoagulable states.26 In addition to hemorrhagic complications, trauma patients are at high risk of venous thromboembolism (VTE), including deep vein thrombosis and/or pulmonary embolism, and accelerated thrombin generation kinetics have been shown to be predictive of VTE development after trauma.27-29 Prior in vitro studies have also shown that thrombin generation in platelet-rich plasma is decreased by neutralization of VWF, suggesting that VWF activates thrombin generation through a platelet-mediated and fibrin-mediated pathway10-12 (figure 1). Increased plasma VWF levels have been associated with poor outcomes after trauma.
specifically after traumatic brain injury (TBI). Additionally, low ADAMTS-13 activity is associated with endothelial damage and mortality in patients with severe trauma. A recent murine model of TBI has demonstrated that administration of exogenous ADAMTS-13 either before or after injury improves neurological function, protects against TBI-induced vascular leakage and consumptive coagulopathy, and reduces mortality without impairment of baseline hemostasis.

In this pilot study, we hypothesized that trauma patients would have greater levels of VWF and decreased levels of ADAMTS-13 compared with healthy volunteers and that trauma patients would have accelerated thrombin generation kinetics.

PATIENTS AND METHODS

Study design and sample source

Patient samples used in this pilot study were collected from a parent prospective case cohort study. Adult patients presenting to the Mayo Clinic Emergency Department as trauma activations were included. Exclusion criteria included age <18 years, refusal of consent or inability to obtain informed consent, ongoing systemic anticoagulation (eg, heparin, warfarin, or novel oral anticoagulants) other than antiplatelet agents (eg, aspirin, clopidogrel, non-steroidal anti-inflammatory drugs), known pre-existing coagulopathy, cirrhosis, active malignancy, sepsis, renal failure requiring dialysis, burn injuries, major surgery or another significant trauma within the last year, pregnant women, or prisoners. The time of injury (TOI) was determined by the prehospital medical providers based on information at the injury scene. Trauma patients or their legal authorized representative (LAR) were consented for this study after the collection of one or more blood samples. If the patient or LAR could not be consented for study participation or declined consent, the sample was destroyed and the patient was excluded. We collected demographic and clinical characteristics for each patient from the electronic medical record. Healthy volunteers were recruited specifically for this study from the local community. Volunteers provided full written informed consent prior to sample collection.

Sample collection, processing, and storage

Blood samples were collected at 0 to 2 hours and at 6 hours after the documented TOI. The collection of samples at 0 to 2 hours was done in the trauma bay, as close to the TOI as possible, but within 2 hours of injury. If a 6-hour sample was unable to be obtained, the baseline sample was still used. A total of 18 mL of whole blood was collected by venipuncture or from indwelling catheters into 4.5 mL citrated Vacutainer tubes (0.105 M buffered sodium citrate, 3.2%; Becton Dickinson, Plymouth, UK), processed to platelet-free plasma by double centrifugation (3000g, 15 minutes) at room temperature (20°C–24°C), as recommended by the International Society on Thrombosis and Haemostasis (ISTH) Vascular Biology Scientific and Standardization Committee (SSC) Collaborative Workshop, and stored in multiple aliquots at −80°C until analysis. All samples were processed into platelet-free plasma within 1 hour of collection.

VWF and ADAMTS-13 analyses

The Rapid Enzyme Assays for Autoimmune Diseases (REAADS) Activity Kit (Corgenix, Broomfield, CO, USA), a sandwich ELISA that measures a monoclonal antibody specific for the platelet-binding A1 region of VWF, was performed per the manufacturer’s instructions using a 1:21 dilution of patient plasma. VWF antigen (VWF:Ag) levels were measured using quantitative sandwich ELISA (Thermo Scientific, Frederick, MD), according to the manufacturer’s instructions, with an 8000-fold dilution of patient plasma. ADAMTS-13 antigen (ADAMTS-13:Ag) levels were measured with sandwich ELISA (R&D Systems, Minneapolis, MN), performed according to the manufacturer’s instructions, using a 100-fold dilution of patient plasma. The ADAMTS-13:Ag to VWF:Ag ratio was also calculated to gauge the relative or kinetic deficiencies of ADAMTS-13.

Statistical analysis

Data analysis was performed using SAS V9.4 (SAS Institute, Cary, NC). Statistics are presented as median values with IQR. Kruskal-Wallis test was used to detect differences in values between trauma and control patients. A p value <0.05 was considered significant. Analysis was performed on all trauma patient samples collected at 0 to 2 hours (n=22) and all samples collected at 6 hours (n=28) separately.
RESULTS

Patient characteristics

A total of 50 plasma samples were collected from 30 trauma patients early after injury (samples collected at 0 to 2 hours from TOI, 6 hours from TOI, or both) and compared with plasma samples from 21 healthy volunteers, collected at a single time point. The median age of the trauma patients was 56 years (31–67), the Injury Severity Score (ISS) was 25.5 (18–32), and 18 of 30 (60%) were male. No patients in this study developed VTE within 90 days of injury. Four (13.3%) of the trauma patients died as a result of their injuries during the index hospital admission. Eleven (36.7%) of the trauma patients received blood transfusions within 24 hours of injury. Of these patients, six underwent massive transfusion per Mayo Clinic Trauma Center Protocol (damage control resuscitation with the goal of 1:1:1 packed red blood cells:plasma:platelets). A total of 20 samples were obtained from the 11 transfused patients, and 6 of these were obtained prior to initiation of any blood products. No patients underwent surgery prior to the collection of samples at 0 to 2 hours, and 14 of 30 (46.7%) underwent surgery prior to the collection of the 6-hour sample. With regard to race, 26 of 30 (86.7%) trauma patients were white, 2 identified as Asian and 1 identified as other. Detailed clinical information on each trauma patient, including ABO blood type, which is known to impact VWF levels, can be found in Table 1.

Among the healthy volunteers, the median age was 43 years (34–56) and 9 of 21 (43%) were male. There was no statistically significant difference in age or sex between trauma patients and volunteers. Among the female volunteers, 7 of 12 (58.3%) were premenopausal, 6 of whom were taking a hormonal

Table 1

| Patient identification | Time points of samples | Additional injuries                                                                 | Transfusion (Y/N) | ISS | ABO blood type |
|-----------------------|------------------------|-------------------------------------------------------------------------------------|------------------|-----|----------------|
| 1                     | 0–2 hours, 6 hours     | TBI                                                                                 | N                | 26  | B+             |
| 2                     | 6 hours                | Facial fractures, TBI                                                                | N                | 24  | A+             |
| 3                     | 0–2 hours, 6 hours     | Rib fractures, scapula fracture, clavicle fracture, pelvic fracture, spine fractures, TBI | Y                | 50  | O+             |
| 4                     | 0–2 hours, 6 hours     | Skull fracture, TBI                                                                  | N                | 26  | O+             |
| 5                     | 6 hours                | Skull base fracture, spine fractures, TBI                                           | N                | 17  | O+             |
| 6                     | 6 hours                | TBI                                                                                 | Y                | 29  | B−             |
| 7                     | 6 hours                | TBI                                                                                 | N                | 29  | O+             |
| 8                     | 0–2 hours, 6 hours     | LB Fx (femur) with vascular injury, facial degloving injury, TBI                     | N                | 38  | A+             |
| 9                     | 6 hours                | Skull fractures, LB Fx (humerus, ulna, radius), TBI                               | N                | 24  | O+             |
| 10                    | 0–2 hours, 6 hours     | Open ankle fracture, TBI                                                            | Y                | 27  | B+             |
| 11                    | 0–2 hours, 6 hours     | TBI                                                                                 | Y                | 26  | AB+            |
| 12                    | 6 hours                | Skull fracture, spine, fractures, LB Fx (tibia/fibula), TBI                        | Y                | 33  | A+             |
| 13                    | 0–2 hours, 6 hours     | Skull base fractures, spine fractures, TBI                                          | Y                | 33  | A+             |
| 14                    | 0–2 hours, 6 hours     | LB Fx, TBI                                                                          | N                | 9   | AB+            |
| 15                    | 0–2 hours, 6 hours     | LB Fx                                                                               | N                | 14  | A+             |
| 16                    | 0–2 hours, 6 hours     | Splenic laceration, LB Fx                                                          | N                | 22  | O+             |
| 17                    | 0–2 hours, 6 hours     | LB Fx                                                                               | Y                | 9   | A−             |
| 18                    | 6 hours                | LB Fx                                                                               | N                | 4   | O+             |
| 19                    | 6 hours                | LB Fx                                                                               | N                | 17  | O+             |
| 20                    | 0–2 hours, 6 hours     | Cardiac injury from stab wound                                                       | Y                | 26  | O+             |
| 21                    | 0–2 hours, 6 hours     | TBI, spine fractures with cord injury, splenic/hepatic/renal lacerations           | Y                | 50  | O+             |
| 22                    | 0–2 hours, 6 hours     | TBI, spine fractures, LB Fx (femoral neck), ankle fracture, rib fractures           | Y                | 22  | A+             |
| 23                    | 0–2 hours, 6 hours     | Superficial lacerations from stab wounds                                            | Y                | 5   | O+             |
| 24                    | 0–2 hours, 6 hours     | TBI, subgaleal hematoma, splenic laceration, mesenteric injury, spine fractures, rib fractures | Y                | 22  | B+             |
| 25                    | 0–2 hours, 6 hours     | LB Fx (tibia and fibula), thigh hematoma, wrist fracture, scapular fracture, rib fractures | Y                | 14  | A+             |
| 26                    | 0–2 hours, 6 hours     | Spine fractures with cord injury, rib fractures                                     | Y                | 25  | A+             |
| 27                    | 0–2 hours, 6 hours     | TBI, LB Fx (bilateral femur)                                                       | Y                | 34  | A−             |
| 28                    | 0–2 hours, 6 hours     | TBI, aortic injury, LB Fx (femur and humerus), ankle fracture, pelvic fracture, spinal fractures, rib fractures | Y                | 34  | AB+            |
| 29                    | 0–2 hours, 6 hours     | Liver laceration                                                                    | Y                | 21  | O+             |
| 30                    | 0–2 hours, 6 hours     | TBI, spine fractures with cord injury, rib fractures                               | Y                | 75  | A+             |

The table shows individual descriptions (de-identified) of the clinical characteristics of the 30 trauma patients in this study including time points of sample acquisition and all clinically relevant injuries.

ISS, Injury Severity Score; LB Fx, long bone fracture; N, no; TBI, traumatic brain injury; Y, yes.
contraceptive, 3 of 12 were perimenopausal, and 2 of 12 were postmenopausal. Regarding race, 20 of 21 volunteers were white (95.2%) and 1 identified as Asian. Blood type was not available for 16 of 21 volunteers, 3 were O+, 1 was A+, and 1 was AB+.

**VWF and ADAMTS-13 levels: trauma patients versus healthy volunteers**

As described in table 2, VWF:Ag levels tended to be greater in trauma patients compared with healthy volunteers both at 0 to 2 hours and at 6 hours; however, this difference did not reach statistical significance.

Healthy volunteers had a broad range of VWF:Ag levels (4.46–128.6 µg/mL), with the greatest value of 128.6 µg/mL in a volunteer exceeding the greatest value in trauma patients of 119.5 µg/mL (range 2.59–119 µg/mL), as can be seen in figure 2. This particular volunteer was an otherwise healthy individual in their 30s with no significant medical or surgical history and met our inclusion criteria based on our standard screening protocol. REAADS activity (exposure of the VWF A1 platelet-binding domain) was significantly greater in trauma patients compared with healthy volunteers at both time points (table 2). However, there was no significant difference in the ratio of REAADS activity to VWF:Ag level at either time point (table 2). ADAMTS-13:Ag levels were significantly decreased in trauma patients at both time points, and ADAMTS-13:Ag to VWF:Ag ratio was significantly lower in trauma patients at 6 hours, as described in table 2.

Patients who received any blood transfusion prior to collection of their 6-hour sample (n=11) were compared with those who did not receive any transfusion (n=17). There was no significant difference found in VWF:Ag level (15.35 µg/mL (14.01–18.65) vs. 27.88 µg/mL (14.28–52.20), p=0.285), ADAMTS-13:Ag level (665 µg/mL (536–854) vs. 643 µg/mL (482–821), p=0.517), or REAADS activity (2706% (2100–7455) vs. 3780% (2762–6636), p=0.329) based on transfusion status.

**Thrombin generation kinetics**

Compared with the healthy volunteers, trauma patients showed accelerated thrombin generation kinetics with significantly decreased ttPeak and increased PH at both time points (table 2). Additionally, patients who received any blood transfusion prior to collection of their 6-hour sample (n=11) were compared with those who did not receive any transfusion (n=17). There were no significant differences in LT (4.00 minutes (3.33–4.74) vs. 4.67 minutes (3.62–5.28), p=0.221), PH (223.7 nM (199.7–237.7) vs. 228.6 nM (183.6–268.0), p=0.547), or ttPeak (7.30 minutes (6.00–8.33) vs. 7.50 minutes (6.28–8.95), p=0.397) between those who were transfused and those who were not.

**DISCUSSION**

We are the first to demonstrate increased exposure of the VWF A1-binding domain in trauma patients using the REAADS assay. This is likely due to the quantitative increase in VWF:Ag level in trauma patients, rather than a conformational change that increases in the intrinsic activity of VWF, as there was no significant difference in the ratio of REAADS activity to VWF:Ag level between trauma patients and healthy volunteers at either
time point in this study. However, we cannot make conclusions regarding conformational changes in VWF with these data alone.

Trauma patients in this study also had significantly decreased ADAMTS-13:Ag levels and ADAMTS-13:Ag to VWF:Ag ratios than healthy volunteers. This indicates a relative deficiency of ADAMTS-13 in trauma patients, potentially due to increased release of ULVWF multimers after trauma, as previously described by Dyer et al. This is also consistent with the findings of Wu et al., who showed improvement in neurological outcomes and reduced mortality in mice that were administered exogenous ADAMTS-13 before or after severe TBI, likely due to increased ULVWF release after injury overwhelming the proteolytic capacity of endogenous ADAMTS-13. Low ADAMTS-13 activity has also been associated with poor outcomes after pediatric trauma.

Trauma patients tended to have increased VWF:Ag levels compared with healthy volunteers at both time points, but this difference was not statistically significant. This differs from other publications, including the recently published study by Dyer et al., who demonstrated a significant increase in the normalized VWF:Ag percentage in trauma patients. This difference is likely due in part to our small sample size, as well as an outlier with a higher than normal VWF:Ag level within our healthy volunteers. As such, individual variation impacted our results.

We also found an accelerated thrombin generation pattern among trauma patients, suggesting that the increased release of VWF after trauma could also be promoting thrombin generation, based on the platelet-driven and fibrin-driven mechanism that has been described in vitro. However, we are unable to draw conclusions about how VWF may influence thrombin generation after trauma based on these data alone.

This study has several limitations. First, this is a small single-center pilot study with primarily blunt trauma and may not be generalizable to other populations. None of the patients in this study developed VTE within 90 days of injury, so we also cannot draw conclusions about the association of VWF with VTE development after trauma, or with other clinical outcomes based on these data alone. Additionally, plasma VWF:Ag level is impacted by a number of factors, including age, race and ABO blood type, and these have can have inter-related effects. Type O blood has been associated with lower plasma VWF:Ag levels than other blood types, which may have impacted our results. Among the trauma group, 12 of 30 patients had type O+ blood (table 1). In the volunteer group, three patients had O+ blood; however, blood type was not available for 16 of 21 healthy volunteers. As such, individual variation impacted our results.

We also found an accelerated thrombin generation pattern among trauma patients, suggesting that the increased release of VWF after trauma could also be promoting thrombin generation, based on the platelet-driven and fibrin-driven mechanism that has been described in vitro. However, we are unable to draw conclusions about how VWF may influence thrombin generation after trauma based on these data alone.

This study has several limitations. First, this is a small single-center pilot study with primarily blunt trauma and may not be generalizable to other populations. None of the patients in this study developed VTE within 90 days of injury, so we also cannot draw conclusions about the association of VWF with VTE development after trauma, or with other clinical outcomes based on these data alone. Additionally, plasma VWF:Ag level is impacted by a number of factors, including age, race and ABO blood type, and these have can have inter-related effects. Type O blood has been associated with lower plasma VWF:Ag levels than other blood types, which may have impacted our results. Among the trauma group, 12 of 30 patients had type O+ blood (table 1). In the volunteer group, three patients had O+ blood; however, blood type was not available for 16 of 21 healthy volunteers. As such, it may be that these groups were not well matched for blood type, which can influence the plasma VWF:Ag level. Additionally, 12 of 21 (57.1%) healthy controls were female, with 6 patients on hormonal contraceptive and 5 patients in varying stages of menopause. Prior work has also suggested some variation in VWF:Ag level based on hormonal shifts, and although data in this area are limited this also may have influenced our results.
Ultimately, prevention of VTE remains a challenge in the trauma population. It is possible that targeted inhibitors that block prothrombotic activity of VWF with minimal impact on hemostasis may represent a future avenue to improve clinical outcomes for patients with severe trauma.48

CONCLUSION

In this pilot study, we showed that trauma patients have significantly increased exposure of the VWF A1 domain and significantly decreased levels of ADAMTS-13 relative to healthy controls. These early findings suggest that the VWF burst after trauma may exceed the proteolytic capacity of ADAMTS-13, allowing circulating ULVWF multimers to bind platelets, potentially contributing to TIC.

Acknowledgements We would like to thank Timothy Halling, Joseph Immerrman, Michael J Ferrara, Andrew Kirmse, and Joel Anderson for their essential contributions to this project in research support, coordination, and data generation. We would also like to thank the Mayo Clinic Center for Translational Science Activities (CTSA) and Clinical Research Unit (CRU) for their ongoing support in specimen collection and processing.

Contributors TAM, JG: data analysis and interpretation, article writing and critical revision. LMT: sample analysis, data acquisition, analysis and interpretation, critical revision of article. AT: study design and conduct, data analysis and interpretation, critical revision of article. KR, GMS, J-FD: study planning, conception and design, data analysis and interpretation, critical revision of article. MA: study planning, conception and design, study conduct, data acquisition, analysis and interpretation, critical revision of article. RK: study planning, conception and design, study conduct, sample and data acquisition, data interpretation, critical revision of article.

Funding This project was supported by R38HL150086 Stimulating Access to Research in Traendiency (TAM) from the National Heart, Lung, and Blood Institute (NHLBI), HL146508 from the National Institute on Aging (NIA) and Robert and Arlene Kogod Center on Aging, Mayo Clinic (JC), RO1 GM 1 26 086–03 (MP) from the National Institute of General Medical Sciences (NIGMS), UM1 HL120877-06 (MP) by the Trans-Agency Consortium for Trauma-Induced Coagulopathy (TACTIC), 1 UL1 RR024150 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), the NIH Roadmap for Medical Research, and by Grant Number U1L TR00135 from the National Center for Advancing Translational Sciences (NCATS).

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval The study was approved by the Mayo Clinic Institutional Review Board (IRB # 418 00481).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. De-identified data used in this study are summarized in this article. Raw data or further de-identified information can be obtained via inquiry to the corresponding author: MP, Division of Trauma, Critical Care and General Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905; Tel: (507) 255-6960, Fax: (507) 255-9872, Park. Myung@mayo.edu.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES

1 Zhou V, Eng ET, Zhu J, Lu C, Walz T, Springer TA. Sequence and structure relationships within von Willebrand factor. Blood 2012;120:449–58.
2 Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998;67:395–424.
3 Wagner DD, Lawrence SO, Olsson-Wilhelm BM, Fay PJ, Marder VJ. Topology and order of formation of interchain disulfide bonds in von Willebrand factor. Blood 1987;69:27–32.
4 Lippok S, Kolliek K, Lof A, Eggert D, Vander Linden W, Müller JP, König G, Obser T, Rohrs K, Schnepfheim S, et al. Von Willebrand factor is dimerized by protein disulfide isomerase. Blood 2016;127:1183–91.
5 Zhou B, Baldus IB, Li W, Edwards SA, Gräfer T. Identification of allosteric disulfides from prestress analysis. Biophys J 2014;107:672–81.
6 Vischer UM, Wagner DD. Von Willebrand factor proteolytic processing and multimerization precede the formation of Weibel-Palade bodies. Blood 1994;83:3536–44.
7 Meyadas TN, Wagner DD. In vitro multimerization of von Willebrand factor is triggered by low pH. Importance of the propolypeptide and free sulfhydryls. J Biol Chem 1989;264:13497–503.
8 Purvis AR, Sadler JE. A covalent oxidoreductase intermediate in propeptide-dependent von Willebrand factor multimerization. J Biol Chem 2004;279:49982–8.
9 Sporn LA, Marder VJ, Wagner DD. Inducible secretion of large, biochemically inactive von Willebrand factor multimers. Cell 1986;46:185–90.
10 Brouland JP, Egan T, Roussi L, Bonneau M, Pignaud G, Bal C, Vaiman M, André P, Hervé M, Mazamzin GM, et al. In vivo regulation of von Willebrand factor synthesis: von Willebrand factor production in endothelial cells after lung transplantation between normal pigs and von Willebrand factor-deficient pigs. Arterioscler Thromb Vasc Biol 1999;19:3055–62.
11 Fowler WE, Fretto L, Hamilton KK, Erickson HP, McKee PA. Substructure of human von Willebrand factor. J Clin Invest 1985;76:1491–500.
12 Aya N, Anvari B, Romo GM, Cruz MA, Dong J-F, McIntyre LV, Moake JL, López JA. Ultrastructural multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-X complex: studies using optical tweezers. Blood 2002;99:9371–7.
13 Furlan M: Von Willebrand factor: molecular and functional activity. Ann Hematol 1996;72:341–3.
14 Siedlecki CA, Lestini B, Kottek-Marchant KK, Eppel SJ, Wilson DL, Marchant RE. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood 1996;88:2939–50.
15 Dong J-Fei, Moake JL, Nolascu L, Bernardo A, Arocena W, Shirampton CN, Schaeje AD, McIntyre LV, Fujikawa K, López JA. ADAMTS-13 rapidly clears newly secreted ultralarge von Willebrand factor multimers from the endothelial surface under flowing conditions. Blood 2002;100:4033–9.
16 Valentijn KM, Eikenboom J. Weibel-Palade bodies: a window to von Willebrand disease. J Thromb Haemost 2013;11:581–92.
17 Choi H, Aboufotouka F, Fowlis NJ, Cook R, Dong J-Fei. Shear-induced disulfide bond formation regulates adhesion activity of von Willebrand factor. J Biol Chem 2007;282:35604–11.
18 Levy GG, Nichols WC, Lian EC, Forouz T, McLintock JN, McGee BM, Yang ZY, Siemieniak DR, Stark KR, Gruppo R, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001;413:488–94.
19 López JA, Dong J-Fei. Shear stress and the role of high molecular weight von Willebrand factor multimers in thrombus formation. Blood Coagul Fibrinolysis 2005;16(Suppl 1):S11–16.
20 Smith NL, Rice KM, Bovill EG, Cushman M, Bis JC, McKnight B, Lumley T, Glazer NL, van Hylckama Vlieg A, Tang W, et al. Genetic variation associated with plasma von Willebrand factor levels and the risk of incident venous thrombosis. Blood 2011;117:6007–11.
21 Sugita C, Yamashita M, Aoyama Y, Iwakiri T, Okajima N, Matsuda S, Matsumoto T, Inoue O, Hanada A, Kitzawa T, et al. Elevated plasma factor VIII enhances venous thrombosis formation in rabbits: contribution of factor XI, von Willebrand factor and tissue factor. Thromb Haemost 2013;110:62–75.
22 Rietveld IM, Lijfering WM, Le Cessie S, Bos MHA, Rosendaal FR, Reitsma PH, Cannegeiter SC. High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor. J Thromb Haemost 2019;17:99–109.
23 Obermeier HL, Riedl J, Ay C, Koder S, Quenemherger P, Bartsch R, Kaidar A, Zielinski CC, Pabinger I. The role of ADAMTS-13 and von Willebrand factor in cancer patients: results from the Vienna cancer and thrombosis study. Res Pract Thromb Haemost 2019;3:303–14.
24 Moake JL, Chow TW. Increased von Willebrand factor (vWF) binding to platelets associated with impaired vWF breakdown in thrombotic thrombocytopenic purpura. J Clin Apher 1998;13:126–32.
25 Fyes HB, Canciani MT, Peyvandi F, Deckmyn H, Vanhoorelbeke K, Mannucci PM. ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. Br J Haematol 2017;183:543–40.
26 Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. J Trauma 2003;54:1127–10.
27 Park MS, Perkins SE, Spears GM, Ashrani AA, Leibson CL, Bos CM, Harmens WS, Jenkins DH, Bailey KR, Ballman KV, et al. Risk factors for venous thromboembolism after acute trauma: a population-based case-cohort study. Thromb Res 2016;144:40–5.
28 Park MS, Xue A, Spears GM, Halling TM, Ferrara MJ, Kunz MM, Dhillon SK, Jenkins DH, Harmens WS, Ballman KV, et al. Thrombin generation and procoagulant microparticle profiles after acute trauma: a prospective cohort study. J Trauma Acute Care Surg 2015;79:726–31.
29 Park MS, Spears GM, Bailey KR, Xue A, Ferrara MJ, Headlee A, Dhillon SK, Jenkins DH, Zietlow SP, Harmens WS, et al. Thrombin generation profiles as predictors of
symptomatic venous thromboembolism after trauma: a prospective cohort study. J Trauma Acute Care Surg 2017;83:381–7.

30 Béguin S, Kumar R, Keularts I, Sellgsohn U, Collier BS, Hemker HC. Fibrin-Dependent platelet procoagulant activity requires GPIb receptors and von Willebrand factor. Blood 1999;93:564–70.

31 Rugeri L, Béguin S, Hemker C, Bordet J-C, Fleury R, Chatard B, Negrier C, Dargaud V. Thrombin-generating capacity in patients with von Willebrand’s disease. Haematologica 2007;92:1639–46.

32 Pelkmans L, Miszta A, Al Dieiri R, de Laat B, Kelchtermans H. Thrombin generation in the presence of platelets is sensitive to the activation status of von Willebrand factor. Thromb Haemost 2015;113:209–11.

33 Yokota H, Nase Y, Nakabayashi M, Unemoto K, Kushimoto S, Kurokawa A, Node Y, Yamamoto Y. Cerebral endothelial injury in severe head injury: the significance of measurements of serum thrombomodulin and the von Willebrand factor. J Neurotrauma 2002;19:1007–15.

34 De Oliveira CO, Reimer AG, Da Rocha AB, Grivich I, Schneider RF, Rosenberg J, Regner A, Simon D. Plasma von Willebrand factor levels correlate with clinical outcome of severe traumatic brain injury. J Neurotrauma 2007;24:1351–8.

35 Russell RT, McDaniell JK, Cao W, Shroyer M, Wagener BM, Zheng XL, Pittet J-F. Low plasma ADAMTS13 activity is associated with coagulopathy, endothelial cell damage and mortality after severe paediatric trauma. Thromb Haemost 2018;118:676–87.

36 Kumar MA, Cao W, Pham HP, Raju D, Nawalinski K, Maloney-Wilensky E, Schuster J, Zheng XL. Relative deficiency of plasma a disintegrin and metallopeptase with thrombospondin type 1 repeats 13 activity and elevation of human neutrophil peptides in patients with traumatic brain injury. J Neurotrauma 2019;36:222–9.

37 Wu Y, Liu Y, Zhou Y, Hilton T, Zhao Z, Liu W, Wang M, Yeon J, Houck K, Thiarajarasing P, et al. Von Willebrand factor enhances microvesicle-induced vascular leakage and coagulopathy in mice with traumatic brain injury. Blood 2018;132:1075–84.

38 Lacroix R, Judzence C, Mooberry M, Bouekine M, Key NS, Dignat-George F. The ISTH SSC Workshop. Standardization of pre-analytical variables in plasma microparticle determination: results of the International Society on thrombosis and haemostasis SSC collaborative workshop. J Thromb Haemost 2013;11:1190–3.

39 Hemker HC. Recollections on thrombin generation. J Thromb Haemost 2008;6:219–26.

40 Hemker HC, Al Dieiri R, De Smedt E, Béguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 2006;96:553–61.

41 Dyer MR, Plaute WE, Ragin MV, Alexander W, Haldeman S, Sperry JL, Guyette FX, Zuckerbraun BS, Rollins-Raval MA, Raval JS, et al. Traumatic injury results in prolonged circulation of ultralarge von Willebrand factor and a reduction in ADAMTS13 activity. Transfusion 2020;60:1308–18.

42 Blann AD. Normal levels of von Willebrand factor antigen in human body fluids. Biologicals 1990;18:351–3.

43 Miller CH, Half E, Platt SJ, Rawlins P, Drews CD, Dilley AB, Evatt B. Measurement of von Willebrand factor activity: relative effects of ABO blood type and race. J Thromb Haemost 2003;1:2191–7.

44 Smith NL, Chen M-H, Dehghan A, Strachan DP, Basu S, Soranzo N, Hayward C, Rudan I, Sabater-Leal M, Bis JC, et al. Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: the charge (cohorts for heart and aging research in genome epidemiology) Consortium. Circulation 2010;121:1382–92.

45 Song J, Chen F, Campos M, Bolgiano D, Houck K, Chambless LE, Wu KK, Folsom AR, Couper D, Boenink E, et al. Quantitative influence of ABO blood groups on factor VIII and its ratio to von Willebrand factor, novel observations from an ARIC study of 11,673 subjects. PLoS One 2015;10:e0132626.

46 Albánez S, Ogiwara K, Michels A, Hopman W, Grabell J, James P, Lillicrap D. Aging and ABO blood type influence von Willebrand factor and factor VIII levels through interrelated mechanisms. J Thromb Haemost 2016;14:963–63.

47 Blomback M, Eneroth P, Landgren BM, Lagenström M, Andersson O. On the intra-individual and gender variability of haemostatic components. Thromb Haemost 1992;67:070–5.

48 Aymé G, Adam F, Legendre P, Bazaï A, Prouillé V, Denis CV, Christophe OD, Lenting PJ. A novel single-domain antibody against von Willebrand factor A1 domain resolves leukocyte recruitment and vascular leakage during inflammation-Brief report. Arterioscler Thromb Vasc Biol 2017;37:1736–40.